CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to HCM

Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine

Phase 3
Hutchmed (HCM)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

2 competitors in Metastatic Pancreatic Cancer

View Full Landscape
Drug Information

Target Indication

Metastatic Pancreatic Cancer

Clinical Trial

NCT06361888

Last updated: 12/13/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals
EMAPending

Sevsury

Treatment of progressive neuroendocrine tumours

View on EMA
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.